Document is current
Any future updates will be listed below
-
Authors
Chantharasamee, Jomjit
Adashek, Jacob J.
Wong, Karlton
Eckardt, Mark A.
Chmielowski, Bartosz
Dry, Sarah
Eilber, Fritz C.
Singh, Arun S.
- License Information
-
More Information
Article History
Accepted: 11 November 2020
First Online: 5 January 2021
Compliance with Ethical Standards
:
: Jomjit Chantharasamee declares that he has no conflict of interest. Jacob J. Adashek declares that he has no conflict of interest. Karlton Wong declares that he has no conflict of interest. Mark A. Eckardt declares that he has no conflict of interest. Bartosz Chmielowski has received compensation for service on advisory boards from IDEAYA Biosciences, Biothera, Epizyme, Deciphera, Iovance Biotherapeutics, Sanofi Genzyme, Regeneron, Eli Lilly, HUYA Bioscience International, Compugen, Array BioPharma, and Merck and has received compensation for service on speakers’ bureaus from Sanofi Genzyme, Regeneron, Janssen, and Genentech. Sarah Dry declares that she has no conflict of interest. Fritz C. Eilber has served on a scientific advisory board for Certis Oncology Solutions. Arun S. Singh has received research support from Bristol-Myers Squibb (grant and provided drug for trial), Eli Lilly, Daiichi Sankyo, Deciphera, NanoCarrier, Eisai, and Blueprint Medicines; has received compensation from Bristol-Myers Squibb, Eli Lilly, Novartis, Daiichi Sankyo, Deciphera, Expert Perspectives, OncLive, Roche, and Blueprint Medicines; and serves on the board of directors and owns stock in Certis Oncology Solutions.
: This article does not contain any studies with human or animal subjects performed by any of the authors.
